Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q

2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain

following cessation of GLP-1s

proof-of-mechanism data for WVE-006 unlocked Wave s

best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address significant unmet needs in cardiometabolic diseases

have five GalNAc-RNA editing or GalNAc-siRNA programs in the clinic by 2026

Wave s clinically validated platform continues to lead on the

improvement of intracellular delivery using novel chemistry, including PN backbone chemistry modifications

Mass., October 30, 2024 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced

updates across its growing pipeline, which were also discussed during the company s virtual analyst and investor Research Day (link to webcast). Updates included new preclinical data for Wave s GalNAc-small interfering RNA (siRNA)

approach for obesity, WVE-007, which is on track to initiate a clinical trial in the first quarter of 2025. Wave also introduced new, wholly owned GalNAc-RNA editing programs and demonstrated its leadership in

oligonucleotide chemistry innovation.

This year, we showed through multiple positive clinical datasets that our leading RNA medicines platform is

opening up new possibilities for the treatment of human disease. Next to the clinic will be our WVE-007 program, which reimagines obesity treatment with a mechanism that directly impacts fat cells

particularly visceral fat and which could be used as monotherapy, add-on to GLP-1s, or for maintenance post-GLP-1 cessation, said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. Additionally, we are excited to introduce three new programs for mRNA correction

and upregulation to treat cardiometabolic diseases with significant unmet needs. These programs have substantial, well-defined patient populations, strong support from human genetics, efficient paths to proof-of-concept in the clinic, and offer the opportunity to meaningfully change health outcomes for millions of people. This truly is an exciting time for Wave and for patients as we unlock new biology and

build our high-value and innovative pipeline.

Key Highlights from Today s Virtual Research Day

WVE-007: INHBE GalNAc-siRNA and potential

best-in-class obesity therapeutic approaching the clinic

New GalNAc-RNA editing programs designed to optimally address high-impact cardiometabolic diseases

innovation enhancing intracellular delivery

An archived webcast of the event can be accessed by visiting Investor Events on the investor relations section of

the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human

health. Wave s RNA medicines platform, PRISM , combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both

rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA

interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave s

diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington s disease, as well as a preclinical program in obesity. Driven by the calling

to Reimagine Possible , Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave s science, pipeline and

people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other

statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data

and completion of our clinical trials, including interactions with regulators and any potential registration based on these data, and the timing and announcement of such events; regulatory submissions and timing for regulatory feedback; the

protocol, design and endpoints of our clinical trials; the future performance and results of our programs in clinical trials; our expectations with respect to how our clinical data successes to date may predict success for our future therapeutic

candidates, future clinical data readouts and further validate of our platform; ongoing and future preclinical activities and programs; the potential of our preclinical data to predict the behavior of our compounds in humans; our identification and

expected timing of future product candidates and their therapeutic potential; the anticipated benefits of our therapeutic candidates and pipeline compared to our competitors; patient population estimates related to our therapeutic candidates and the

potential addressable market that our therapeutics may address; our ability to design compounds using various modalities and the anticipated benefits of that approach; the breadth and versatility of our PRISM drug discovery and development platform;

the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the potential benefits of our RNA editing capability, including our AIMers, compared to others; the benefits of RNA medicines generally; the

potential for certain of our programs to be best-in-class or first-in-class; the

potential benefits that our edit-verse may provide us, including identifying new RNA editing targets; our ability to translate genetic insights into high impact medicines; the status and progress of our programs relative to potential

competitors; the progress and potential benefits of our collaborations; ;and the anticipated duration of our cash runway and our ability to fund future operations. The words may, will, could, would,

should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue,

target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on

management s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of

these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled Risk Factors in Wave s most recent Annual Report on Form

10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in

this press release to reflect subsequently occurring events or circumstances.